Approximately 35 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT)